Literature DB >> 15307922

Characterization of molecular features, antigen-binding, and in vitro properties of IgG and IgM variants of 4E10, an anti-HIV type 1 neutralizing monoclonal antibody.

Renate Kunert1, Susanne Wolbank, Gabriela Stiegler, Robert Weik, Hermann Katinger.   

Abstract

The human monoclonal antibody 4E10 has been generated previously by immortalization of peripheral blood cells from an HIV-1-infected individual. This antibody binds to the linear epitope NWFDIT on gp41 and exhibits exceptional neutralizing activity against a broad spectrum of primary HIV-1 isolates. In the present study, molecular features, immunoreactivity, and functional activity of 4E10 were studied. The original hybridoma-derived 4E10 was of subtype IgG(3). Analysis of the variable segment of the heavy chain (VH) demonstrated extensive somatic mutations compared to the closest homologous germline gene VH1-69. Most amino acid substitutions occurred in the complementarity-determining region (CDR) 2, characteristic for an antigen-driven somatic maturation. The heavy chain of the CDR3 (H3) is of unusual length and cannot be attributed with certainty to any specific D(H) locus. To enable mass production and to prolong the in vivo half-life, 4E10 was subsequently cloned as IgG(1) in Chinese hamster ovary (CHO) cells. In additional studies, 4E10 was class switched to the IgM isotype. Binding to the linear epitope NWFDIT was not significantly changed after the cloning procedures. However, in vitro studies revealed dramatic differences in the neutralizing potential. The antiviral activity could be greatly enhanced by change of IgG(3) to IgG(1). In contrast, the IgM isotype almost completely lost its neutralizing potential.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15307922     DOI: 10.1089/0889222041524571

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  35 in total

1.  HIV-1 gp140 epitope recognition is influenced by immunoglobulin DH gene segment sequence.

Authors:  Yuge Wang; Pratibha Kapoor; Robert Parks; Aaron Silva-Sanchez; S Munir Alam; Laurent Verkoczy; Hua-Xin Liao; Yingxin Zhuang; Peter Burrows; Michael Levinson; Ada Elgavish; Xiangqin Cui; Barton F Haynes; Harry Schroeder
Journal:  Immunogenetics       Date:  2015-12-19       Impact factor: 2.846

2.  Adjunctive passive immunotherapy in human immunodeficiency virus type 1-infected individuals treated with antiviral therapy during acute and early infection.

Authors:  Saurabh Mehandru; Brigitta Vcelar; Terri Wrin; Gabriela Stiegler; Beda Joos; Hiroshi Mohri; Daniel Boden; Justin Galovich; Klara Tenner-Racz; Paul Racz; Mary Carrington; Christos Petropoulos; Hermann Katinger; Martin Markowitz
Journal:  J Virol       Date:  2007-08-08       Impact factor: 5.103

3.  Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10.

Authors:  Joshua S Klein; Priyanthi N P Gnanapragasam; Rachel P Galimidi; Christopher P Foglesong; Anthony P West; Pamela J Bjorkman
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-16       Impact factor: 11.205

4.  Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region.

Authors:  Elin S Gray; Maphuti C Madiga; Penny L Moore; Koleka Mlisana; Salim S Abdool Karim; James M Binley; George M Shaw; John R Mascola; Lynn Morris
Journal:  J Virol       Date:  2009-08-19       Impact factor: 5.103

5.  Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1.

Authors:  Miroslaw K Gorny; Xiao-Hong Wang; Constance Williams; Barbara Volsky; Kathy Revesz; Bradley Witover; Sherri Burda; Mateusz Urbanski; Phillipe Nyambi; Chavdar Krachmarov; Abraham Pinter; Susan Zolla-Pazner; Arthur Nadas
Journal:  Mol Immunol       Date:  2008-10-25       Impact factor: 4.407

6.  Aromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactions.

Authors:  Erin M Scherer; Daniel P Leaman; Michael B Zwick; Andrew J McMichael; Dennis R Burton
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-04       Impact factor: 11.205

7.  A conformational switch in human immunodeficiency virus gp41 revealed by the structures of overlapping epitopes recognized by neutralizing antibodies.

Authors:  Robert Pejchal; Johannes S Gach; Florence M Brunel; Rosa M Cardoso; Robyn L Stanfield; Philip E Dawson; Dennis R Burton; Michael B Zwick; Ian A Wilson
Journal:  J Virol       Date:  2009-06-10       Impact factor: 5.103

8.  Anti-HIV B Cell lines as candidate vaccine biosensors.

Authors:  Takayuki Ota; Colleen Doyle-Cooper; Anthony B Cooper; Michael Huber; Emilia Falkowska; Katherine J Doores; Lars Hangartner; Khoa Le; Devin Sok; Joseph Jardine; Jeffrey Lifson; Xueling Wu; John R Mascola; Pascal Poignard; James M Binley; Bimal K Chakrabarti; William R Schief; Richard T Wyatt; Dennis R Burton; David Nemazee
Journal:  J Immunol       Date:  2012-10-12       Impact factor: 5.422

9.  Few and far between: how HIV may be evading antibody avidity.

Authors:  Joshua S Klein; Pamela J Bjorkman
Journal:  PLoS Pathog       Date:  2010-05-27       Impact factor: 6.823

10.  TRAIL-receptor 1 IgM antibodies strongly induce apoptosis in human cancer cells in vitro and in vivo.

Authors:  Xiuhong Piao; Tatsuhiko Ozawa; Hiroshi Hamana; Kiyomi Shitaoka; Aishun Jin; Hiroyuki Kishi; Atsushi Muraguchi
Journal:  Oncoimmunology       Date:  2016-05-04       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.